AI Is Driving Change in Oncology Practice and Commercialization. Are You Part of the Wave?

Posted by Shankar Viswanathan on Feb 15, 2018 9:15:07 AM

Arup Das co-wrote this blog post with Shankar Viswanathan.

Looking back at 2017, artificial intelligence and machine learning made impressive progress when it comes to improving cancer diagnosis and treatment. Using deep learning, computers are scouring images to detect signs of breast cancer in mammograms earlier than humans are currently capable of. Using AI “random forests,” a learning algorithm, investigators are more accurately predicting which drug combination will work better in BRAF mutant melanoma. The AI-facilitated discovery of Berg Health’s BPM 31510, a pancreatic cancer drug, has entered human development clinical trials. AI is not only powering oncology drug discovery, faster detection and personalized treatment but also helping to improve oncology commercialization effectiveness and agility through analytics. 


>
Read More

Five Ways to Leap Into Competitive Execution in Oncology

Posted by Namita Kalyan on Jan 10, 2018 8:00:00 AM

Scott Cohen co-wrote this blog post with Namita Kalyan.

You may have heard this old adage: Three frogs are sitting on a log. One of them decides to leap off. How many frogs are left on the log? The answer is still three frogs. There’s a difference between deciding to do something and actually doing it—and that difference is execution.


>
Read More

Behind the Consultant Curtain: Leveraging Your Segment’s Strengths

Posted by Malik Kaman on Jan 8, 2018 8:00:00 AM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part two in a two-part series.

In our previous post, we discussed the four typical “segments” of oncology companies:

  1. Original Innovators: High prior oncology success, low commercial sophistication
  2. The Space Invaders: Low prior oncology success, high commercial sophistication
  3. The New Kids on the Block: Low prior oncology success, low commercial sophistication
  4. The Vanguard: High prior oncology success, high commercial sophistication

>
Read More

Going Beyond the Buzz of CAR-T Therapy

Posted by Robert Rovner on Dec 21, 2017 10:21:09 AM

There’s no doubt that chimeric antigen receptor T-cell (CAR-T) therapies have been generating increased interest over the past four years at the American Society of Hematology’s (ASH) Annual Meeting. In 2014, 34 abstracts on CAR-T therapies were presented at ASH, a number that more than tripled to 110 abstracts by 2016. This year, more than 140 CAR-T abstracts were presented to a packed Georgia World Congress Center in Atlanta. While some questions about this novel approach to cancer treatment remain unanswered, one thing is for certain: CAR-T therapies are here to stay. 


>
Read More

Upending the Treatment Paradigm in AML

Posted by Nathan Noll on Dec 19, 2017 9:40:13 AM

Sony introduced the Walkman in 1979. At the time, it was revolutionary, but when compared with the technology available today, it is woefully outmatched.


>
Read More